# Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Study · id `cardio:ct-nct07537088` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07537088](<https://clinicaltrials.gov/study/NCT07537088>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07537088

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 468 participants.

## Technical summary

Registry record NCT07537088. Randomized; no masking; primary purpose treatment. Start 2026-05 (anticipated); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 468 participants (planned count; ClinicalTrials.gov record NCT07537088, source copy `cardio:ctgov-nct07537088-2026-04-22`, retrieved 2026-10-26)
- Planned start: 2026-05 (anticipated) (ClinicalTrials.gov record NCT07537088, source copy `cardio:ctgov-nct07537088-2026-04-22`, retrieved 2026-10-26)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT07537088, source copy `cardio:ctgov-nct07537088-2026-04-22`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07537088, source copy `cardio:ctgov-nct07537088-2026-04-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07537088-2026-04-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Condition: CKD - Chronic Kidney Disease
- Intervention (Drug): Dulaglutide
- Intervention (Drug): SGLT2i
- Intervention (Drug): Finerenone
- Lead sponsor: First Affiliated Hospital of Wannan Medical College
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Wannan Medical College (`cardio:org-first-affiliated-hospital-of-wannan-medical-college`)

## Provenance

Content hash: 7c962b561aaba63eed43f35df2f295e7919d1064860dcbbba1d4eb48f2d2d045
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
